American Heart Association Comment: Tirofiban -- The Platelet Receptor Blocker For Heart Attack

May 20, 1998

Two new studies in the New England Journal of Medicine on tirofiban (Aggrastat) show that the drug may be useful in the treatment of heart attack.

"Tirofiban is a novel drug that will open the door to new treatments for the preceding stages of heart attack or the heart attack itself," says Valentin Fuster, M.D., Ph.D., president-elect of the American Heart Association, commenting on two studies.

Tirofiban is a member of a class of drugs called "platelet glycoprotein receptor blockers." As the name suggests, the drug blocks the action of platelets, cells that clump to help form a blood clot.

The drugs have been used to improve the results of angioplasty -- a blood vessel-opening procedure -- by preventing reclosure of blood vessels, a common problem. But last week the Food and Drug Administration approved tirofiban for individuals with unstable angina (chest pain at rest) and non-Q-wave myocardial infarction (limited heart attack). These conditions result from blood clots that have not totally or persistently blocked the blood vessel feeding the heart, but they may precede complete blockage leading to heart attack.

"People with those conditions often have to have surgical interventions such as angioplasty. Tirofiban may help some patients avoid surgery for a short time or totally," says Fuster. "By postponing angioplasty, one can buy time during which other treatments can be applied to lower blood cholesterol and blood pressure."

The treatment advance has resulted from a better understanding of the causes of heart attack.

"We know that heart attack involves a complex process, but one of the final triggers is a blood clot that blocks the blood vessel. By interfering with clot formation, antiplatelet drugs like tirofiban can help prevent a heart attack," he says.

One study looked at the effect of tirofiban in individuals with unstable angina or non Q-wave myocardial infarction. After seven days, individuals on tirofiban and heparin (a blood thinner) had a 32 percent reduced risk of death, heart attack or ischemia compared to a group who received heparin alone. In the second study, after 48 hours individuals with unstable angina taking tirofiban had a reduced risk of 32 percent compared to those receiving heparin.

How often the drug treatment will replace angioplasty or other treatments to remove blockages and relieve chest pain is still unknown. The study found that the major benefits from the drug came immediately, but after a few months those treated with tirofiban were no better off than those receiving heparin.

"As the author of the accompanying editorial in NEJM suggests, 'short-term therapy appears inadequate for a long-term disease,'" says Fuster. "The drug helps treat the tip of the iceberg, but individuals may need more ways to fight the underlying disease -- atherosclerosis. This means not smoking, keeping blood cholesterol and blood pressure levels down and increasing physical activity.

"The best way is to prevent the blood clot in the first place," says Fuster, who was one of the first scientists to show that blood clots that cause heart attack are derived from platelet clumps on top of the fatty buildup, called plaque, that characterize atherosclerosis. Fuster is director of the Cardiovascular Institute, Mount Sinai Medical Center, New York.

For interviews or more information, please contact Carole Bullock of the AHA's News Media Relations department at (214) 706-1279.

American Heart Association

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to